BOLD Boundless Bio
-
Boundless Bio Reported Earnings
Friday, August 7, 2026 · 12:00 AM ET
Boundless Bio (BOLD) reported a loss of $1.06 per share on revenue of $0.00 million for the second quarter ended June 2026. .
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($1.06)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—